These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

343 related items for PubMed ID: 3390830

  • 1. Genetic instability and the development of steroid hormone insensitivity in cultured T 47D human breast cancer cells.
    Reddel RR, Alexander IE, Koga M, Shine J, Sutherland RL.
    Cancer Res; 1988 Aug 01; 48(15):4340-7. PubMed ID: 3390830
    [Abstract] [Full Text] [Related]

  • 2. Mechanisms involved in the evolution of progestin resistance in human breast cancer cells.
    Murphy LC, Dotzlaw H, Wong MS, Miller T, Murphy LJ.
    Cancer Res; 1991 Apr 15; 51(8):2051-7. PubMed ID: 1849041
    [Abstract] [Full Text] [Related]

  • 3. Differential sensitivity of human breast cancer cell lines to the growth-inhibitory effects of tamoxifen.
    Reddel RR, Murphy LC, Hall RE, Sutherland RL.
    Cancer Res; 1985 Apr 15; 45(4):1525-31. PubMed ID: 3978620
    [Abstract] [Full Text] [Related]

  • 4. Modulation of the growth-inhibitory effects of progestins and the antiestrogen hydroxyclomiphene on human breast cancer cells by epidermal growth factor and insulin.
    Koga M, Musgrove EA, Sutherland RL.
    Cancer Res; 1989 Jan 01; 49(1):112-6. PubMed ID: 2642286
    [Abstract] [Full Text] [Related]

  • 5. Differential effects of phorbol ester on epidermal growth factor receptors in estrogen receptor-positive and -negative breast cancer cell lines.
    Koga M, Musgrove EA, Sutherland RL.
    Cancer Res; 1990 Aug 15; 50(16):4849-55. PubMed ID: 2379149
    [Abstract] [Full Text] [Related]

  • 6. Effects of pharmacological concentrations of estrogens on proliferation and cell cycle kinetics of human breast cancer cell lines in vitro.
    Reddel RR, Sutherland RL.
    Cancer Res; 1987 Oct 15; 47(20):5323-9. PubMed ID: 3652038
    [Abstract] [Full Text] [Related]

  • 7. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
    Menendez JA, Oza BP, Colomer R, Lupu R.
    Int J Oncol; 2005 Jun 15; 26(6):1507-15. PubMed ID: 15870863
    [Abstract] [Full Text] [Related]

  • 8. Stimulation of c-myc oncogene expression associated with estrogen-induced proliferation of human breast cancer cells.
    Dubik D, Dembinski TC, Shiu RP.
    Cancer Res; 1987 Dec 15; 47(24 Pt 1):6517-21. PubMed ID: 3677090
    [Abstract] [Full Text] [Related]

  • 9. Factors affecting the sensitivity of T-47D human breast cancer cells to tamoxifen.
    Reddel RR, Murphy LC, Sutherland RL.
    Cancer Res; 1984 Jun 15; 44(6):2398-405. PubMed ID: 6722780
    [Abstract] [Full Text] [Related]

  • 10. T47DCO cells, genetically unstable and containing estrogen receptor mutations, are a model for the progression of breast cancers to hormone resistance.
    Graham ML, Krett NL, Miller LA, Leslie KK, Gordon DF, Wood WM, Wei LL, Horwitz KB.
    Cancer Res; 1990 Oct 01; 50(19):6208-17. PubMed ID: 2400987
    [Abstract] [Full Text] [Related]

  • 11. Antiestrogen binding in antiestrogen growth-resistant estrogen-responsive clonal variants of MCF-7 human breast cancer cells.
    Miller MA, Lippman ME, Katzenellenbogen BS.
    Cancer Res; 1984 Nov 01; 44(11):5038-45. PubMed ID: 6488162
    [Abstract] [Full Text] [Related]

  • 12. p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells.
    Liang Y, Wu J, Stancel GM, Hyder SM.
    J Steroid Biochem Mol Biol; 2005 Feb 01; 93(2-5):173-82. PubMed ID: 15860260
    [Abstract] [Full Text] [Related]

  • 13. Characterization of estrogen and progesterone receptors and the dissociated regulation of growth and progesterone receptor stimulation by estrogen in MDA-MB-134 human breast cancer cells.
    Reiner GC, Katzenellenbogen BS.
    Cancer Res; 1986 Mar 01; 46(3):1124-31. PubMed ID: 3943090
    [Abstract] [Full Text] [Related]

  • 14. A metastatic breast tumor cell line, GI-101A, is estrogen receptor positive and responsive to estrogen but resistant to tamoxifen.
    Morrissey JJ, Raney S.
    Cell Biol Int; 1998 Mar 01; 22(6):413-9. PubMed ID: 10328849
    [Abstract] [Full Text] [Related]

  • 15. Expression and regulation of retinoic acid receptors in human breast cancer cells.
    Roman SD, Clarke CL, Hall RE, Alexander IE, Sutherland RL.
    Cancer Res; 1992 Apr 15; 52(8):2236-42. PubMed ID: 1313739
    [Abstract] [Full Text] [Related]

  • 16. Endocrine-responsive pancreatic carcinoma: steroid binding and cytotoxicity studies in human tumor cell lines.
    Benz C, Hollander C, Miller B.
    Cancer Res; 1986 May 15; 46(5):2276-81. PubMed ID: 3697973
    [Abstract] [Full Text] [Related]

  • 17. Estradiol induction of retinoic acid receptors in human breast cancer cells.
    Roman SD, Ormandy CJ, Manning DL, Blamey RW, Nicholson RI, Sutherland RL, Clarke CL.
    Cancer Res; 1993 Dec 15; 53(24):5940-5. PubMed ID: 8261407
    [Abstract] [Full Text] [Related]

  • 18. Effect of medroxyprogesterone acetate on proliferation and cell cycle kinetics of human mammary carcinoma cells.
    Sutherland RL, Hall RE, Pang GY, Musgrove EA, Clarke CL.
    Cancer Res; 1988 Sep 15; 48(18):5084-91. PubMed ID: 2970295
    [Abstract] [Full Text] [Related]

  • 19. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.
    Chu I, Blackwell K, Chen S, Slingerland J.
    Cancer Res; 2005 Jan 01; 65(1):18-25. PubMed ID: 15665275
    [Abstract] [Full Text] [Related]

  • 20. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM.
    J Natl Cancer Inst; 2005 Sep 07; 97(17):1254-61. PubMed ID: 16145046
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.